I give up.
You just double, nay triple up on the stupid comments. Not on the FDA radar? The FDA granted CYP orphan drug designation for CYP-0001 in GVHD back in 2018 for crying out loud? It has IND status clearance in its Phase II trial in GVHD for Pete's sake?
I heard Johnson & Johnson still test on rats on occasion. Should I sell my holdings there too, by your logic? They must be going back to their 1886 ways do you think? Likewise. I recall MSB trading at $8 when I first heard of it. Should we all just give up on it given I once saw it trade there? By your logic in having seen CYP trade at $1.80?
Sector has gone Gavin, no need to blindly punch out anymore. Autologous, allogeneic, stromal, mesenchymal, chondrocytes, neural, pluripotent, embryonic stem cells, etc, etc, will all likely co-exist in a stem-cell embracing world across dozens if not hundreds of companies and thousands of medical applications.
We do not live in a singular world of MSB vs CYP success in GVHD or other applications. You can go and get many Mesenchymal stem cells treatments in Australia right now outside of these two companies - you might want to do a little reading on the types of stem cells CYP uses if you insist on arguing with CYP holders. The two and many others can co-exist simultaneously commercially and will do so with other companies in various facets and types of stem cell treatments and approaches, as will MSB and CYP at some point - yes, yes Gavin, MSB before.
Are you even aware of how many stem cell approvals the FDA has already granted? I will give you a clue, its first was effectively in Hemacord in 2011. Its been rather busy beyond the myopic CYP vs MSB (vs FDA) world you live in, in granting approval to quite a few not unrelated therapies since beyond your MSB vs CYP universe:
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-productsThose conservative FDA antagonists of yours, so far behind the advanced world of MSB, let alone those crazy CYP cats and their scary IPSC's, somehow managed to approve a couple of treatments that enable enable modification of patients’ hematopoietic (blood) stem cells by genome editing.
And you think IPSC's or Cynata "not even on the FDA radar".
. Yours seems to be on the blip again.
(20min delay)